Analysts expect Axovant Gene Therapies Ltd (NASDAQ:AXGT) to announce earnings per share of ($0.99) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Axovant Gene Therapies’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($1.28). Axovant Gene Therapies posted earnings per share of ($3.84) in the same quarter last year, which would suggest a positive year-over-year growth rate of 74.2%. The business is expected to issue its next quarterly earnings report on Tuesday, August 6th.
On average, analysts expect that Axovant Gene Therapies will report full-year earnings of ($6.59) per share for the current year, with EPS estimates ranging from ($9.92) to ($3.49). For the next year, analysts forecast that the business will post earnings of ($5.87) per share, with EPS estimates ranging from ($8.08) to ($3.65). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Axovant Gene Therapies.
Axovant Gene Therapies (NASDAQ:AXGT) last released its quarterly earnings data on Tuesday, June 11th. The company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.70) by $1.25.
A number of analysts have recently weighed in on the stock. Chardan Capital upgraded shares of Axovant Gene Therapies from a “neutral” rating to a “buy” rating and set a $32.00 price objective on the stock in a research note on Monday, March 11th. HC Wainwright reiterated a “buy” rating and issued a $56.00 price objective on shares of Axovant Gene Therapies in a research note on Tuesday, March 12th. JMP Securities reiterated an “outperform” rating and issued a $48.00 price objective (down previously from $64.00) on shares of Axovant Gene Therapies in a research note on Monday, March 11th. Zacks Investment Research upgraded shares of Axovant Gene Therapies from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a research note on Wednesday, April 10th. Finally, ValuEngine upgraded shares of Axovant Gene Therapies from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 9th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Axovant Gene Therapies has a consensus rating of “Buy” and a consensus price target of $36.20.
Shares of NASDAQ:AXGT traded up $0.23 during midday trading on Friday, reaching $5.08. The company’s stock had a trading volume of 17,440 shares, compared to its average volume of 457,167. The firm has a market capitalization of $95.22 million, a P/E ratio of -0.66 and a beta of 1.39. Axovant Gene Therapies has a twelve month low of $3.81 and a twelve month high of $33.12. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.63 and a quick ratio of 2.02.
Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in Axovant Gene Therapies during the first quarter valued at $3,430,000. Jefferies Group LLC purchased a new position in Axovant Gene Therapies during the first quarter valued at $3,354,000. Primecap Management Co. CA purchased a new position in Axovant Gene Therapies during the first quarter valued at $1,400,000. Macquarie Group Ltd. purchased a new position in Axovant Gene Therapies during the first quarter valued at $1,150,000. Finally, Morgan Stanley purchased a new position in Axovant Gene Therapies during the first quarter valued at $291,000.
About Axovant Gene Therapies
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Read More: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.